Endothelial cell density change in fully dislocated XEN Gel IMPLANT after trabeculectomy: A case report

Purpose: To report a case of fully dislocated XEN Gel Implant device into the anterior chamber, 18 months after its implantation and its impact on endothelial cell density. Result: A 75-year-old man with a history of multiple glaucoma surgeries during the last three years presented with an entirely dislocated XEN Gel implant into the anterior chamber. An endothelial cell density reduction was observed over 18 months. Thus, the implant was removed. In the short-term after surgery, the endothelial cell loss rate reduced. Conclusion: XEN Gel Implant can dislocate into the anterior chamber, increasing endothelial cell loss in an eye already underwent multiple surgical procedures with subsequent adverse events. Therefore, if the implant seems displaced, the endothelial cell density should be monitored, and the length of the free-tube segment within the anterior chamber should be measured, during the patient’s follow-up.

[1]  I. Ahmed,et al.  XEN® Gel Stent: A Comprehensive Review on Its Use as a Treatment Option for Refractory Glaucoma , 2020, Clinical ophthalmology.

[2]  A. Bron,et al.  European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma. , 2020, Journal of cataract and refractive surgery.

[3]  L. Au,et al.  Conjunctival bleb compression as a treatment for hypotony post XEN45 implant in uveitic glaucoma , 2020, European journal of ophthalmology.

[4]  C. Gupta,et al.  XEN® stent complications: a case series , 2019, BMC Ophthalmology.

[5]  G. Reiss,et al.  Safety and Effectiveness of CyPass Supraciliary Micro-Stent in Primary Open-Angle Glaucoma: Five-Year Results from the COMPASS XT Study. , 2019, American journal of ophthalmology.

[6]  A. Mermoud,et al.  Anterior Chamber XEN Gel Stent Movements: The Impact on Corneal Endothelial Cell Density. , 2019, Journal of glaucoma.

[7]  S. Morselli,et al.  XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice , 2018, Clinical ophthalmology.

[8]  J. Kalenak.  Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. , 2018, American journal of ophthalmology.

[9]  Young H. Kwon,et al.  Glaucoma-associated corneal endothelial cell damage: A review. , 2017, Survey of ophthalmology.

[10]  S. Morselli,et al.  Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent , 2018, International Ophthalmology.

[11]  N. Dervenis,et al.  Dislocation of a previously successful XEN glaucoma implant into the anterior chamber: a case report , 2017, BMC Ophthalmology.

[12]  G. Holló.  Wound Healing and Glaucoma Surgery: Modulating the Scarring Process with Conventional Antimetabolites and New Molecules. , 2017, Developments in ophthalmology.

[13]  I. Ahmed.  MIGS and the FDA: What's in a Name? , 2015, Ophthalmology.

[14]  S. Yoshida,et al.  Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis , 2014, BMC Ophthalmology.

[15]  A. Coleman,et al.  Dynamic Tube Movement of Ahmed Glaucoma Valve , 2009, Journal of glaucoma.

[16]  Dao-Yi Yu,et al.  The critical role of the conjunctiva in glaucoma filtration surgery , 2009, Progress in Retinal and Eye Research.

[17]  Chang Sik Kim,et al.  Changes in corneal endothelial cell density and morphology after Ahmed glaucoma valve implantation during the first year of follow up , 2008, Clinical & experimental ophthalmology.

[18]  Corneal endothelial photography. Three-year revision. American Academy of Ophthalmology. , 1997, Ophthalmology.